Digital Innovations In Vaccine Safety (DIVaS)

Effective safety monitoring of COVID-19 vaccines must go beyond the use of passive surveillance, which is typically used to monitor vaccine safety and generate a hypothesis, to the use of active surveillance that systematically collects more complete data that can support hypothesis testing as well. DIVaS’s aim is to develop a standardized protocol for the conduct of cohort event monitoring (CEM) among healthcare workers in low- and middle-income countries (LMICs) to answer the question “What observed adverse events following immunization (AEFIs) are attributable to the COVID-19 vaccines?  

DIVaS is currently working to create a standardized cohort event monitoring protocol to systematically collect information on short- and long-term adverse events following immunization (AEFI) from 50,000 healthcare workers (HCWs) receiving a COVID-19 vaccine in at least five developing countries using mobile phones. This will be complementary to other CEM studies to be supported by the WHO in other countries. 

More of Our Work